Oncodesign Precision Medicine (FRA:ZR8) Total Equity: €52.88 Mil (As of Dec. 2025)


FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
38 GF Score
Price €0.30
GF Value €0.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Total Equity?

Oncodesign Precision Medicine FRA:ZR8 38 Total Equity is €52.88 Mil as of Dec. 2025. GuruFocus rates FRA:ZR8 with a GF Score™ of 38/100 and a GF Value™ of €0.26 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Oncodesign Precision Medicine's total equity for the quarter that ended in Dec. 2025 was €52.88 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Oncodesign Precision Medicine Total Equity Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Total Equity Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 4.20 11.78 3.69 -0.43 52.88

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.69 3.14 -0.43 10.40 52.88
FRA:ZR8
38GF Score
Oncodesign Precision Medicine SA FRA:ZR8
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Oncodesign Precision Medicine's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.988--37.889
=52.88

Oncodesign Precision Medicine's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14.988--37.889
=52.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €52.88 Mil mean?
Oncodesign Precision Medicine (FRA:ZR8) has a Total Equity of €52.88 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Total Equity too high?
Oncodesign Precision Medicine's current Total Equity is €52.88 Mil. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Total Equity compare to VRTX and REGN?
Oncodesign Precision Medicine's Total Equity of €52.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Total Equity is €52.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current Total Equity is €52.88 Mil. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Total Equity is €52.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for FRA:ZR8:

  • Total Equity: €52.88 Mil
  • GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score

Get the complete analysis for FRA:ZR8

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.26
GF Value